Workflow
Licensing agreements
icon
Search documents
Getty Images (GETY) - 2025 Q4 - Earnings Call Transcript
2026-03-16 21:32
Financial Data and Key Metrics Changes - For the full year 2025, the company reported record revenue of $981.3 million, representing a year-over-year growth of 4.5% and 3.8% on a currency neutral basis [4][5] - Adjusted EBITDA for the full year was $320.9 million, with a margin of 32.7%, both metrics exceeding the high end of guidance [5][25] - In Q4 2025, revenue reached $282.3 million, a year-over-year increase of 14.1% and 12.7% on a currency neutral basis [5][13] - Q4 adjusted EBITDA was $104.1 million, up 29.1% reported and 27.2% on a currency neutral basis, with a margin of 36.9% [5][25] Business Line Data and Key Metrics Changes - Creative revenue in Q4 was $149 million, up 4.6% year-on-year, driven by accelerated revenue from two large licensing deals, despite a 16% decline in agency revenue [20] - Editorial revenue for Q4 was $109.4 million, up 21.4% year-on-year, with growth across all four verticals: news, sport, entertainment, and archive [21][22] - Annual subscription revenue grew 1% year-over-year, with Premium Access, the largest subscription, up 4.1% in Q4 [18] Market Data and Key Metrics Changes - The Americas region saw a revenue increase of 20.8% in Q4 on a currency neutral basis, while EMEA was up 6.1% and APAC down 13% due to challenges in the agency business [17] - Active annual subscribers totaled 278,000 in Q4, down from 314,000 in the previous year, primarily due to the discontinuation of the free trial program [19] Company Strategy and Development Direction - The company aims to strengthen its recurring revenue base and expand long-term partnerships, as evidenced by securing significant multi-year licensing agreements [6][7] - Continued investment in machine learning capabilities to enhance content discovery and customer experience is a strategic focus [10] - The company is optimistic about future growth opportunities in video and custom AI training sets, indicating a proactive approach to evolving market demands [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's durable business model, highlighting strong customer relationships and a diversified revenue mix as key strengths [4][11] - The company anticipates a revenue range of $948 million to $988 million for 2026, reflecting a decline due to the timing of revenue recognition from large licensing agreements [32][34] - Management noted that the core business is expected to grow, excluding the impact of challenging year-on-year comparisons from the previous year [35] Other Important Information - The company reported a decrease in free cash flow to $7.7 million in Q4, attributed to higher cash interest expenses [27][28] - Total debt outstanding was $2.01 billion as of December 31, 2025, with a net leverage of 4.0x [29][30] Q&A Session Summary Question: Insights on licensing deals and their long-term applicability - Management highlighted the relevance of content in social media and large language models as key drivers for the licensing deals, indicating potential for more such agreements in the future [38][39] Question: Reasons for decline in active annual subscribers and retention rates - The decline in active annual subscribers was primarily due to the end of the free trial program, with expectations for retention rates to improve as the impact cycles through [40][42] Question: Clarification on 2026 revenue guidance and data licensing - Management clarified that the large deals recognized in Q4 are not purely data licensing deals, and while there is a pipeline for future deals, specifics are not included in the 2026 guidance [47][49]
Biodexa Pharmaceuticals PLC(BDRX) - Prospectus(update)
2023-12-06 22:15
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON DECEMBER 6, 2023 Registration No. 333-274895 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Biodexa Pharmaceuticals PLC (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorporation or Organization) England and Wales 2834 Not Applicable (Primary Standard Industrial Classification Code Number) (IRS Employer ...